Response to “Letter to the editor on the paper: The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing”

Detalles Bibliográficos
Autores principales: van Kempen, Zoé LE, Rispens, Theo, Killestein, Joep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Letters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5971362/
https://www.ncbi.nlm.nih.gov/pubmed/28990853
http://dx.doi.org/10.1177/1352458517734073
_version_ 1783326276134633472
author van Kempen, Zoé LE
Rispens, Theo
Killestein, Joep
author_facet van Kempen, Zoé LE
Rispens, Theo
Killestein, Joep
author_sort van Kempen, Zoé LE
collection PubMed
description
format Online
Article
Text
id pubmed-5971362
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-59713622018-06-05 Response to “Letter to the editor on the paper: The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing” van Kempen, Zoé LE Rispens, Theo Killestein, Joep Mult Scler Letters SAGE Publications 2017-10-09 2018-05 /pmc/articles/PMC5971362/ /pubmed/28990853 http://dx.doi.org/10.1177/1352458517734073 Text en © The Author(s), 2017 http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Letters
van Kempen, Zoé LE
Rispens, Theo
Killestein, Joep
Response to “Letter to the editor on the paper: The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing”
title Response to “Letter to the editor on the paper: The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing”
title_full Response to “Letter to the editor on the paper: The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing”
title_fullStr Response to “Letter to the editor on the paper: The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing”
title_full_unstemmed Response to “Letter to the editor on the paper: The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing”
title_short Response to “Letter to the editor on the paper: The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing”
title_sort response to “letter to the editor on the paper: the majority of natalizumab-treated ms patients have high natalizumab concentrations at time of re-dosing”
topic Letters
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5971362/
https://www.ncbi.nlm.nih.gov/pubmed/28990853
http://dx.doi.org/10.1177/1352458517734073
work_keys_str_mv AT vankempenzoele responsetolettertotheeditoronthepaperthemajorityofnatalizumabtreatedmspatientshavehighnatalizumabconcentrationsattimeofredosing
AT rispenstheo responsetolettertotheeditoronthepaperthemajorityofnatalizumabtreatedmspatientshavehighnatalizumabconcentrationsattimeofredosing
AT killesteinjoep responsetolettertotheeditoronthepaperthemajorityofnatalizumabtreatedmspatientshavehighnatalizumabconcentrationsattimeofredosing

Ejemplares similares